+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Quarterly intravenous ibandronate for postmenopausal osteoporosis

Quarterly intravenous ibandronate for postmenopausal osteoporosis

Women's Health 4(3): 219-228

Osteoporosis is under-recognized and undertreated among postmenopausal women. Nitrogen-containing bisphosphonates are its first-line pharmacotherapy. Oral bisphosphonate treatment requires stringent dosing guidelines to minimize gastrointestinal irritation and enhance absorption. This paper reviews the efficacy, safety and tolerability of quarterly intravenous ibandronate 3 mg injection, approved in 2006 in the USA and Europe. Quarterly intravenous ibandronate injection has shown superior efficacy to daily oral ibandronate for bone mineral density increase and fracture prevention. No drug-related serious atrial fibrillation events have been reported with intravenous ibandronate. The regimen has a favorable renal safety profile. Quarterly intravenous ibandronate is administered as a simple 15-30-s intravenous injection in a physician's office and provides a beneficial option for patients who are unable to tolerate oral administration.

(PDF emailed within 0-6 h: $19.90)

Accession: 055328045

Download citation: RISBibTeXText

PMID: 19072470

DOI: 10.2217/17455057.4.3.219

Related references

Quarterly intravenous injection of ibandronate to treat osteoporosis in postmenopausal women. Clinical Interventions in Aging 2(1): 65-72, 2007

Quarterly intravenous ibandronate injections provide continuing benefits in women with postmenopausal osteoporosis: DIVA study long-term extension. 2007

Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis and Rheumatism 54(6): 1838-1846, 2006

Tri-monthly intravenous injections of ibandronate for treatment of postmenopausal osteoporosis. Journal of Bone & Mineral Research 16(Suppl 1): S406, September, 2001

Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. American Journal of Medicine 103(4): 298-307, 1997

Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review. Current Pharmaceutical Design 11(28): 3711-3728, 2005

Renal tolerability of intermittent intravenous ibandronate treatment for patients with postmenopausal osteoporosis: a review. Clinical and Experimental Rheumatology 26(6): 1125-1133, 2009

Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 34(5): 890-899, 2004

Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice. Clinical Drug Investigation 33(2): 117-122, 2013

Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. Journal of Rheumatology 35(3): 488-497, 2008

Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension. Osteoporosis International 23(6): 1769-1778, 2012

Effects of intermittent intravenous ibandronate injections on bone quality and micro-architecture in women with postmenopausal osteoporosis: the DIVA study. Bone 46(3): 660-665, 2010

Effects of intravenous ibandronate injection on renal function in women with postmenopausal osteoporosis at high risk for renal disease – the DIVINE study. Bone 49(6): 0-1322, 2011

Effects of intravenous ibandronate injection on renal function in women with postmenopausal osteoporosis at high risk for renal disease--the DIVINE study. Bone 49(6): 1317-1322, 2012

Clinical efficacy and safety of monthly oral ibandronate 100 mg versus monthly intravenous ibandronate 1 mg in Japanese patients with primary osteoporosis. Osteoporosis International 26(11): 2685-2693, 2016